晚期非小细胞肺癌病人血清组织多肽抗原水平对预后的影响  

INFLUENCE OF SERUM TPA LEVEL ON THE PROGNOSIS OF PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER

作　　者：宋玉华[1] 刘华[1] 沈方臻[1] 姚如永[1] 

机构地区：[1]青岛大学医学院附属医院肿瘤治疗研究中心,山东青岛266003

出　　处：《齐鲁医学杂志》2005年第6期508-509,共2页Medical Journal of Qilu

摘　　要：①目的探讨晚期非小细胞肺癌(NSCLC)病人血清组织多肽抗原(TPA)水平对病人预后的影响。②方法对78例晚期NSCLC病人给予4～6周期化疗,其中24例辅助放疗。所有病人在治疗前抽血测血清TPA。③结果34例病人(43.6%)血清TPA水平升高,其1年生存率为11.6%,2年生存率为0。血清TPA水平正常的病人1年生存率为56.8%,2年生存率为13.6%。两者生存率差异有显著性(χ2=3.95,P<0.05)。Cox多因素分析表明,病人的预后与TPA水平(P=0.000)和疗效(P=0.047)有关。④结论血清TPA水平可作为判断晚期NSCLC病人预后的一个独立指标。Objective To evaluate the influence of serum TPA level on the prognosis of patients with advanced non-small-cell lung cancer（NSCLC）. Methods Seventy eight NSCLC patients received chemotherapy four to six cycles, of whom, 23 cases received adjuvant radiotherapy. All were detected for serum TPA before the treatment. Results Increased serum TPA levels were noted in 34 patients（43.6%）, those with increased serum TPA levels had an one-year survival rate of 11.6% and two-year survival was zero; those with normal serum TPA, one-year survival rate was 56. 8%, and two-year survival was 13.6%. The difference of survival was significant between the two groups （χ^2 =3.95 ,P〈0.05）. Cox multiple factor analysis showed that the prognosis of the patients was related to the serum TPA levels （P=0. 000） and the efficacy of treatment （P=0.047）. Conclusion TPA can be used as an independent prognostic parameter in advanced NSCLC.

关 键 词：癌 非小细胞肺 组织多肽抗原 预后 

分 类 号：R734.2[医药卫生—肿瘤]